Response Pharmaceuticals to Present Data on RDX-002 in Antipsychotic-Induced Weight Gain at the 2026 American Psychiatric Association Annual Meeting

Response Pharmaceuticals to Present Data on RDX-002 in Antipsychotic-Induced Weight Gain at the 2026 American Psychiatric Association Annual Meeting

Poster presentation will highlight Phase 1b data on RDX-002, an investigational, first-in-class, gut-restricted inhibitor of intestinal MTP in development for atypical antipsychotic-induced weight gain, a leading driver of treatment discontinuation among patients on atypical antipsychoticsFALLS CHURCH, Va.--(BUSINESS WIRE)--#AIWG--Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for weight managemen…